List view / Grid view

Acorda Therapeutics

Filter the results



Acorda to acquire Biotie; gains rights to tozadenant

19 January 2016 | By Victoria White

In acquiring Biotie for approximately $363 million, Acorda will obtain worldwide rights to tozadenant, an oral adenosine A2a receptor antagonist currently in Phase 3 development in Parkinson’s disease...